Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
NCT02510794
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
225
Enrollment
INDUSTRY
Sponsor class
Conditions
Macular Degeneration
Interventions
DRUG:
Ranibizumab
Sponsor
Genentech, Inc.